SCHEMBL30097697

SCHEMBL30097697

CN(C(=O)c1cc(Cl)cc(Cl)n1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 3/20 0.55
POLB P06746 2/20 0.50
KMT2A Q03164 3/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
PLAU P00749 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
LMNA P02545 1/20 0.44
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAOB P27338 1/20 0.42
PTGS2 P35354 1/20 0.41
ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23413189 1.00 GPBAR1 (0.55) GPBAR1POLBKMT2AKDM4EMAPT
SCHEMBL23413305 0.80 MAPT (0.46) GPBAR1POLBKMT2AKDM4EMAPT
SCHEMBL30097705 0.80 MAPT (0.46) GPBAR1POLBKMT2AKDM4EMAPT
SCHEMBL20339015 0.78 TP53 (0.55) KMT2ASMN1; SMN2LMNAMEN1NPC1
SCHEMBL23413303 0.76 GPBAR1 (0.40) GPBAR1POLBKMT2AKDM4EMAPT
SCHEMBL30097629 0.76 GPBAR1 (0.40) GPBAR1POLBKMT2AKDM4EMAPT
SCHEMBL23558023 0.76 ATM (0.58) GPBAR1POLBKMT2AKDM4EMAPT
SCHEMBL812900 0.75 KDM4E (0.56) POLBKMT2AKDM4EMAPTPLAU
SCHEMBL23413164 0.74 ABCC1 (0.44) GPBAR1POLBKMT2AKDM4EMAPT
SCHEMBL23412641 0.74 MAPT (0.46) GPBAR1KMT2AKDM4EMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115348959-B Heteroaryl compounds and their therapeutic use in conditions associated with altered beta-glucocerebrosidase activity GT增益治疗股份有限公司 2025-01-07 CN disclosed
CN-115348959-A Heteroaryl compounds and their therapeutic use in disorders associated with altered beta-glucocerebrosidase activity 增益治疗股份有限公司 2022-11-15 CN disclosed